Background: It is unknown why functional gastrointestinal disorders (FGIDs) overlap
| INTRODUCTION
Functional gastrointestinal disorders (FGIDs) are common disorders, and represent a variable combination of chronic or recurrent gastrointestinal (GI) symptoms not explained by known structural or biochemical abnormalities. [1] [2] [3] [4] Overlap of FGIDs has been widely reported in the literature. [5] [6] [7] [8] [9] While such overlap with other GI disorders and/or extra-intestinal disorders might simply reflect a chance association due to the high prevalence of the disorders, several studies have confirmed that the overlap of FGIDs occurs more frequently than expected, indicating this is not likely a chance event. [8] [9] [10] Moreover, one FGID. [9] [10] [11] In addition, studies have shown that gastroesophageal reflux (GER) symptoms commonly co-exist in a considerable proportion of patients with upper or lower FGIDs. [8] [9] [10] 12, 13 In a meta-analysis for the co-existence of irritable bowel syndrome (IBS) and GER, Lovell and Ford reported that the odd ratio of GER in individuals with IBS was fourfold that of individuals without IBS. 12 Moreover, in a systematic review, Gerson et al. showed that dyspeptic symptoms were present in 38% of subjects with GER. It is conceivable that the overlap between FGIDs including GER is not coincidence, but rather reflects a common underlying pathophysiology. For example, somatization and psychological disorders frequently co-exist with these functional disorders. 9, 14 However, the intimate interrelationship between GER and FGIDs is often not considered when assessing risk factors (and is not part of the Rome criteria). Although the Rome criteria have been conceptually developed to maximize homogeneity within each functional gut disorder (supporting the conduct of clinical trials and pathways to drug approval), and while GER is not traditionally considered an FGID, physicians commonly encounter patients with multiple upper and lower GI symptoms in the clinic setting. Furthermore, the majority of studies assessing overlap of FGIDs have been focused on the association of only one or two FGIDs (most notably IBS or functional dyspepsia), and there are few data on risk factors for overlap of these conditions.
Because little is still known about the overlap of multiple FGIDs in the community, understanding the role of risk factors in overlap groups could expose differences in underlying pathophysiology, which has implications in terms of the development of new targeted therapies. Thus, we aimed to estimate the prevalence of combinations of FGIDs including GER (FGIDs-GER), and evaluate the potential risk factors including somatization for people with multiple disorders in a representative US community.
| MATERIALS AND METHODS
A population-based study was conducted with subjects selected from an age-and gender-stratified community random sample sent a GI symptom survey in 2008-2009 which included validated GI symptom questions. This study was approved by the Institutional Review
Boards of Mayo Clinic and Olmsted Medical Center.
| Subjects
The study milieu has been described in prior publications, but in brief 15-18 the Olmsted County, Minnesota, population comprises approximately 120 000 people of which 89% are white; sociodemographically, this community closely resembles the USA white population and results can be generally extrapolated to that population segment. Mayo Clinic is the major provider of medical care 16 and the Rochester Epidemiology Project records linkage system provides essentially an enumeration of the population allowing random samples to be identified and selected. 16 These data resources have been utilized in a series of investigations into the epidemiology of functional GI disorders. 9, [19] [20] [21] [22] As approved by the
Institutional Review Boards of Mayo Clinic and Olmsted Medical
Center, we used this system to draw a series of random samples of Olmsted County residents stratified by age (5-year intervals between 20 and 94 years) and sex (equal numbers of men and women).
| Survey methods
For this study, a previously assembled age-and gender-stratified random sample (n=8006) 
26
Priming letters were initially mailed to highlight that a GI questionnaire would be sent. Later, an explanatory letter accompanied the survey which was mailed to a total of 8006 Olmsted County residents.
Reminder letters were mailed at weeks 3-6 after the initial mailing to non-responders. Subjects who indicated at any point that they did not wish to complete the survey were not contacted further. Otherwise,
Key Points
• The co-existence of upper and lower FGIDs as well as gastroesophageal reflux (GER) symptoms is common in the community.
• Younger age, female gender, and higher somatization score are important risk factors for overlapping FGID-GER complexes.
• The higher the somatization score, the more likely the overlap of FGID-GER complexes suggesting a dose-response like effect.
non-responders were contacted by telephone at week 9 to request 
| Definition of symptom categories
Subjects were classified into a priori symptom groups based on their responses to the questionnaires, which recorded their symptoms over the past 3 months. Subjects could have more than one disorder. Slight modifications of the Rome III criteria were used to categorize subjects.
| Symptom categories

Gastroesophageal reflux
This was defined by one or more of the following traditional reflux
1. Heartburn (retrosternal burning pain), at least once a week 1 day/ week in the last 3 months.
2.
Acid regurgitation, at least 1 day/week in the last 3 months.
Functional dyspepsia
This was defined by symptom criteria of Rome III, 2 with one or more of following (for more than 6 months); (i) unable to finish a regular size meal more than once a week, (ii) feels uncomfortably full after regular size meal more than once a week, and (iii) pain or burning in the upper middle abdomen (epigastrium) at least once a week (above the umbilicus).
Functional bloating
Bloating was defined by Rome III criteria, 1 recurrent feeling of bloating in abdomen or visible distension, at least 3 days/month in the last 3 months.
Irritable bowel syndrome
Irritable bowel syndrome was defined by Rome III criteria, 1 namely pain or discomfort at least 2 or 3 days per month and 2 or more of the following at least sometimes; (i) pain relieved by bowel movements,
(ii) change in frequency (more or fewer), and (iii) change in consistency (looser or harder).
Functional constipation
Functional constipation was defined by Rome III criteria, 1 all three criteria below had to be met: 
2.
Loose stools rarely present without the use of laxatives.
Insufficient criteria for IBS.
Functional diarrhea
Functional diarrhea was defined by Rome III criteria, 1 loose or watery stools without pain (occurring in at least 75% of stools) except if loose stools were due to laxative use. Criterion fulfilled for the last 3 months
with symptom onset at least 6 months prior to diagnosis.
Pure or overlap of FGID-GER complexes
Using responses from the BDQ, a pure FGID-GER (that met only one of the criteria for GER, dyspepsia, IBS, bloating, constipation, or diarrhea), 2 FGIDs-GER (that had any two-way combinations of GER, dyspepsia, IBS, bloating, constipation, or diarrhea), or 3 or more FGIDs-GER (that had any three-way combinations of GER, dyspepsia, IBS, bloating, constipation, or diarrhea) were categorized.
| Statistical analysis
The associations of sociodemographic features, SSC scores, medication use, and physician visits with multiple overlap of FGIDs-GER (defined as a pure FGID-GER, 2 FGIDs-GER, or 3 or more FGIDs-GER) were evaluated using polychotomous logistic regression models. The odds ratios (OR) for overlap (and 95% CI) were estimated from the coefficients (and their standard errors) obtained in the polychotomous logistic regression models. A P-value (two-tailed) of <.05 was considered statistically significant. All analyses utilized the SAS ® statistical analysis package (SAS Institute Inc., Cary, NC, USA).
| RESULTS
| Prevalence of each FGID and overlap of FGIDs-GER
Of the 3831 responders, 3548 subjects provided data for each of the necessary symptom questions for this study. The mean age of the eligible subjects was 61 years and 54% were female. Figure 1 shows the age-and sex-adjusted prevalence of each FGID-GER symptom complexes in a community.
The overall age-and sex-adjusted prevalence of each syndrome in the community were as follows; 8% had GER, 7% had dyspepsia, 15% had IBS, 13% had bloating, 5% had constipation, and 2% had diarrhea. Among these 3548 subjects, 2009 (57%) had no FGIDs-GER, 906 (26%) had a pure FGID-GER, 372 (10%) had 2 FGIDs-GER, and 261 (7%) had 3 or more FGIDs-GER (Figure 2 ). Table 1 shows the clinical features of subgroups according to the FGIDs-GER combination status. Notably, subjects reporting combinations of FGIDs-GER were younger, more likely to be of female gender, have higher SSC scores, and report more physician visits relative to subjects without any FGID-GER. Especially, subjects with three or more FGIDs-GER had the highest SSC scores, the most physician visits, and the highest proportion of medication usage, including proton pump inhibitors (PPI), calcium channel blockers, antispasmodic agents, antidepressants, or narcotics. Table 2 shows the SSC score according to the number of FGID-GER complexes. In subjects with three or more FGIDs-GER, the mean total SSC score was 1.5 (±0. 8) , that is, the highest score among the groups, and the means of the individual SSC scores were also the highest.
| Somatization score in combination of FGIDs-GER
For all individual SSC items, the more subjects having FGIDs-GER, the greater the SSC scores. Figure 3 shows the mean scores of often, bothersome, and total SSC scores according to FGIDs-GER status. The mean scores for often, bothersome, and total SSC scores increased stepwise with the number of FGIDs indicating a dose-response like relationship. with lesser numbers of FGIDs-GER. Furthermore, medication usage (including PPI, antispasmodic use, antidepressants, and narcotics), was also associated with an increased odds for those with three or more FGIDs-GER compared to a pure FGID-GER or no FGIDs-GER.
| Potential risk factors for combination of FGIDs-GER
The comparison between a pure FGID-GER and no FGIDs-GER is summarized in Table S1 . Since the GER symptom group was likely to be heterogeneous, we further assessed the potential risk factors for pure GER, a pure FGID, GER with 2 or more FGIDs, or 3 or more FGID without GER (Table S1 ). Even though GER was separated, the overall findings were similar.
T FGID, functional gastrointestinal disorders; GER, gastroesophageal reflux; PPI, proton pump inhibitors.
Bold indicates statistical significance. Table 4 shows the OR for total and each SSC score for 3 or more 
| Relationship between the number of FGIDs-GER and SSC scores
| DISCUSSION
In this study, we found significant proportions of people in the community experienced a combination of FGIDs-GER symptoms; the overall proportion reporting two combination of FGIDs-GER was estimated to be 10% and the proportion of three or more FGIDs-GER was 7% in this representative US community. We observed that younger age, female gender, higher somatic symptom score, more physician visits and more medication usage were significantly associated with increased numbers of FGID-GER complexes relative to subjects free of these FGID-GER symptom complexes. Of interest, people who have more FGID-GER complexes were significantly more likely to also report features traditionally attributed to somatization. Overall, those with a high somatic symptom score were 8. commonly co-exist with other distinct disorders, including fibromyalgia, chronic fatigue syndrome, temporomandibular joint disorder, chronic pelvic pain, and interstitial cystitis more often than expected by chance. 14, [35] [36] [37] [38] We found that more than half of subjects who had a finding yet to be adequately explained.
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Although we applied modified criteria from Rome III criteria for
FGIDs, it was reassuring that we observed the overall age-and gender adjusted prevalence of GER was 8%, dyspepsia 7%, IBS 15%, bloating 13%, constipation 5%, and diarrhea 2% in a representative community sample, all prevalence rates very similar to prior studies in Olmsted County 20, 26, 62 and elsewhere. 4, 63 This suggests selection bias is unlikely to account for our findings. Further responders were similar to non-responders in this study. In other research from Olmsted County,
we have shown response bias is extremely low risk in responders to the BDQ. 28 The strengths of this study include the investigation of a random community sample. We avoided just studying health care seeking subjects which should have minimized or avoided selection bias. Symptom-based criteria of FGIDs are well accepted, and a carefully validated questionnaire was applied. Limitations of our work include the lack of detail about psychological and psychiatric conditions including depression or anxiety status. Furthermore, we cannot conclude that there is a definite causal association between symptom-based GI disorders and somatization disorders because of the inherent difficulties in a cross-sectional study design. A possible additional limitation was a lack of clinical detail regarding structural disease, although in most cases, we would expect investigations to be negative or normal as others have confirmed. 64 Despite these limitations, this study presents important characteristics of the overlap of multiple FGIDS group in a community. While our data may not be generalized to the whole US population because the racial composition of this community is predominantly white, and while the prevalence of GI symptom complexes may vary by ethnic group, at a minimum our data are generalizable to Caucasians across the United States.
In summary, this study provides strong evidence of the coexistence of multiple FGIDs with GER in a community. Our results also demonstrate that overlap of FGIDs is common rather than rare in the community and is not explained by chance. The findings support common pathophysiological pathways in the FGIDs and GER. Higher somatization scores, that is, more severe and frequent somatic symptoms, are a risk factor for multiple FGID-GER complexes. Further studies including large, prospective, and longitudinal approaches comprehensively assessing gut and extra-intestinal symptoms are warranted. We conclude that symptom complex overlap is common in the community and multiple somatic symptoms are a major risk factor for overlap of FGIDs and GER.
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